CardioNova recruits first patient in Phase I/IIa clinical trial of AHRO-001 aimed at treatment of dyslipidemia and prevention of atherosclerosis

Skolkovo Biomedical Cluster Resident "CardioNova", founded with investments from Maxwell Biotech Venture Fund founded with the participation of RVC, announced today enrollment of the first volunteers with mild to moderate hyperlipidemia in a randomized, double-blind placebo controlled Phase I/IIa clinical trial. The study is aimed to assess safety, tolerability, pharmacokinetics and preliminary efficacy of a short-term reception of the lead compound AHRO-001. Approximately 70 patients will take part in this trial.

During the clinical trial will be studied the interaction between the projected drug AHRO-001 and atorvastin, the current “gold standard” in dyslipidemia therapy. The trial will be held in two Moscow study centers.

Cardiovascular diseases remain the biggest cause of deaths worldwide. One of the main factors for cardiovascular pathologies progression is dyslipidemia (increase in cholesterin level) that results in vessel arterial sclerotic disease. As a result, the risk for such acute ischemic conditions as myocardial infarction, apoplectic attack, as well as limb ischemia, increases considerably.

Preclinical studies, conducted in partnership with AtheroNova, a public US company, demonstrated that use of AHRO-001 resulted not only to a significant reduction in cholesterol levels, but also induced significant regression of atherosclerotic plaques reduction (by up to 94%) in the various vessels. No currently marketed drug has evidence of so strong potency in plaque regression.

Andrey Boldyrev, CEO of “CardioNova”: “We are delighted that after the preclinical studies, which have shown safety and efficacy of AHRO-001, this clinical trial has started. The successful accomplishment of Phase I/IIa clinical trial can afford the company to move to the next efficacy phase of studies in patients, suffering from cardiovascular diseases”.

About CardioNova

"CardioNova", Ltd is a private biotechnology company, founded in 2011 to develop and launch into the Russian market innovative products to treat cardiovascular disease. Since December 2011 “CardioNova” has become a resident of Skolkovo Biomed Cluster. The first product (AHRO-001) is aimed at treatment and prevention of atherosclerosis dysplipidemia and developed in the framework of international cooperation with public biotech company AtheroNova, Inc. (OTC: AHRO).

cardionova.ru